NorthWest Biotherapeutics Inc (NWBO)

[j e d]

The more I’ve thought about this AACR debacle, the more I think this could be a blessing in disguise. Where they might not have reported results beforehand, they could now be the first major medical outlet to report the trial’s success—and word would propagate from there.

This hinges on them not just retracting their report on DCVax, but issuing a full account based on the NYAS presentation—passed both primary and secondary endpoints with flying colors, long tail, first hope for GBM patients in 17 years, applicable to all solid tumors, etc.